Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Heron Therapeutics Inc (HRTX) Price & Performance

Bitwise Crypto Industry Innovators ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Bitwise Crypto Industry Innovators ETF vs Heron Therapeutics Inc — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $23.72, while Heron Therapeutics Inc trades at $0.43 (market cap $82.52M). The key difference: Bitwise Crypto Industry Innovators ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

BITQHRTX
Sector
Crypto-linkedHealth
52-Week High
$30.43$2.04
52-Week Low
$16.74$0.39
Market Cap
$82.52M
Enterprise Value
$180.42M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitwise Crypto Industry Innovators ETF

BITQ trades at $23.18, down 3.13% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators show neutral conditions. Support levels cluster around $23-24 while resistance sits at $25-26. Recent news highlights investor rotation away from crypto-related ETFs as Bitcoin prices decline, creating headwinds for BITQ's performance.

The outlook remains cautious given the bearish technical setup and sector-specific challenges. Investment opportunity exists for contrarian investors betting on crypto market recovery, but risks include continued ETF outflows and regulatory uncertainty. The stock's performance remains tightly correlated with broader cryptocurrency sentiment rather than standalone fundamentals.

Heron Therapeutics Inc

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.

Returns comparison

Trailing returns across standard periods

About Bitwise Crypto Industry Innovators ETF

BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.

Read more on BITQ

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX